I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $182.14M | ||||
Company | Location |
Date | Amt. (M) |
Details |
Actimis |
San Diego |
4/28/05 |
$6 |
Sanderling Ventures led the Series A financing, which also included Mitsui & Co. Venture Partners; Actimis was spun out of Bayer HealthCare AG |
Affectis |
Munich, Germany |
4/13/05 |
€4 (US$5.17) |
The Series B financing round was led by EMBL Ventures; additional new investors Adamant, KfW and Sunrise Water Ltd. joined existing investors LSP, BayernKapital and the Max Planck Society |
Ambrx Inc. |
San Diego |
4/8/05 |
$23.4 |
The second-round financing included new investors Maverick Capital, CMEA Ventures, Twilight Venture Partners and Alexandria Real Estate Equities and existing investors Tavistock Life Sciences, 5AM Ventures, Versant Ventures and Aravis Ventures |
Anthera |
San Francisco |
4/21/05 |
ND |
The new company completed a Series A financing |
CellCentric |
Cambridge, UK |
4/7/05 |
£0.25 (US$0.47) |
The Rainbow Seed Fund invested in the financing that adds on to the company's initial round |
DNage BV |
Rotterdam, the Netherlands |
4/13/05 |
€1.5 (US$2) |
Inventages Venture Capital and Life Sciences Partners invested in the seed round of the firm, which was spun out of Erasmus Medical Center |
GeneOhm Sciences Inc. |
San Diego |
4/1/05 |
ND |
Partners HealthCare System Inc. invested in the company in a follow-on Series C financing |
Gentris Corp. |
Morrisville, N.C. |
4/27/05 |
$5 |
Mitsui & Co. (U.S.A.) Inc. provided funding for the Series C financing round |
Hamilton |
Washington |
4/22/05 |
$11.1 |
Founding investors Vivo Ventures LLC and CNF Investments LLC were joined by Index Ventures in the Series A financing |
Ikaria Inc. |
Seattle |
4/26/05 |
ND |
The new company received investments from ARCH Venture Partners, Venrock Associates, 5AM Ventures, Aravis Ventures and the Washington Research Foundation |
Ipsat |
Helsinki, Finland |
4/4/05 |
€7 (US$9) |
The financing round was led by Bio Fund Management Oy, with Finnish Industry Investment Ltd., the Varma Mutual Pension Insurance Co. and Sitra also investing |
Merrimack |
Cambridge, Mass. |
4/20/05 |
$37.3 |
The financing comprises $28.3M of Series D stock and a $9M venture loan; existing invest- ors Sorenson Development Inc., Unilever Technology Ventures Fund BV and Wharton Biotech- nology Partners were joined by WT Investment Advisors; the loan was provided by Hercules Technology Growth Capital |
Molecular Insight Pharmaceuticals Inc. |
Cambridge, Mass. |
4/21/05 |
$28 |
New investors Siemens Venture Capital GmbH Corp., Tudor Investment Corp., MedCap Management & Research LLC and Emigrant Capital Corp. joined existing investors in the Series C financing round; SG Cowen & Co. was placement agent |
NanoString |
Seattle |
4/27/05 |
$3.8 |
Series A investors that invested $4.3M in August 2004 increased the round to $8.1M by exercising warrants in full; the investors were Draper Fisher Jurvetson and OVP Venture Partners |
Oxford Genome |
Oxford, UK |
4/4/05 |
ND |
The South East Growth Fund led the second- round financing, and Oxford Capital Partners joined as a new investor |
Receptor |
South San Francisco |
4/28/05 |
$33.6 |
Skyline Ventures led the Series A financing, which also included Domain Associates, Essex Woodlands Health Ventures, MedImmune Ventures, Takeda Research Investment Inc. and Northwest Technology Ventures |
Syntarga BV |
Nijmegen, the Netherlands |
4/15/05 |
ND |
Aglaia Oncology Fund led the Series A financing, with BioPartner Start-up Ventures as co- investor |
Talecris |
Research Triangle Park, N.C. |
4/1/05 |
ND |
The company was formed from the purchase of Bayer HealthCare LLC's plasma business; Cerberus Capital Management LP and Ampersand Ventures provided financing for Talecris |
Ventaira |
Columbus, Ohio |
4/4/05 |
$13.5 |
TL Ventures led the Series C round, which included Battelle Ventures, Battelle, Safeguard Scientific, PA Early Stage Partners, Fletcher Spaght Ventures LP, Reservoir Venture Partners and James Richardson & Sons Ltd. |
Xceleron Ltd. |
Heslington, UK |
4/28/05 |
£2 (US$3.8) |
Close Venture Management led the financing round with a £1.5M investment, while Foursome Investments provided £0.5M |
II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $13.0M | ||||
EntreMed |
Celgene Corp. |
$10.5 |
Warrants exercise |
Celgene exercised 7M warrants at $1.50 each that it received in a December 2002 deal in which EntreMed licensed its thalidomide analogue program to Celgene (4/1) |
Ligand |
TAP Pharmaceuticals Products Inc. |
$1.5 |
Milestone payment |
Triggered by TAP's submission of an IND to evaluate LGD2941, a product from their collaboration, for treating osteoporosis and frailty (4/4) |
Maxim |
Myriad Genetics Inc. |
$1 |
Milestone payment |
Triggered by dosing of the first patient in Myriad's Phase I program to evaluate safety and pharmacokinetics of MPC-6827 in patients with advanced solid tumors (4/27) |
Pharmacopeia |
Schering-Plough Corp. |
ND |
Milestone payment |
Triggered by Schering-Plough's initiation of preclinical development of a small-molecule drug candidate identified in their collaboration targeted at inflammatory disease (4/13) |
Notes: | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
* Private company. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
ND = Not disclosed. | ||||
